HIV vaccine - GenStar

Drug Profile

HIV vaccine - GenStar

Alternative Names: LENTI-HIV; MAXIMUM-AD HIV

Latest Information Update: 11 Jun 2007

Price : $50

At a glance

  • Originator University of California System
  • Developer Corautus Genetics
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 06 Jun 2007 Corautus Genetics has since been acquired and merged into VIA Pharmaceuticals
  • 15 Aug 2003 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 16 Jun 2000 Preclinical development for HIV infections treatment in USA (Unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top